Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer
Open Access
- 25 July 2017
- journal article
- research article
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 23, 3627-3634
Abstract
BACKGROUND:Clinical monitoring of EGFR-positive NSCLC patients is important to gauge treatment response. The current study addresses the usage of circulating tumor DNA (ctDNA) as a prognostic marker during treatment of first-generation TKIs. MATERIAL...Keywords
This publication has 33 references indexed in Scilit:
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerScience Translational Medicine, 2015
- Circulating Tumor DNA as a Liquid Biopsy for CancerClinical Chemistry, 2015
- Molecular Biology of Lung CancerChest, 2013
- K-ras Mutations in the Plasma Correspond to Computed Tomographic Findings in Patients With Pancreatic CancerPancreas, 2012
- Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate CancerClinical Cancer Research, 2009
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibClinical Cancer Research, 2006
- Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRNature Genetics, 2005
- Repeat needle biopsies combined with clinical observation are safe and accurate in the management of a solitary pulmonary noduleCancer, 2005
- Early Lung Cancer Action ProjectCancer, 2001